4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $42.56.

Several research analysts have recently commented on the stock. Royal Bank of Canada lowered their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Leerink Partners restated an “outperform” rating and issued a $36.00 price target (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Chardan Capital restated a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its position in shares of 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after buying an additional 67,202 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of 4D Molecular Therapeutics by 81.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock worth $265,000 after purchasing an additional 11,002 shares during the last quarter. State Street Corp increased its position in shares of 4D Molecular Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after purchasing an additional 37,232 shares in the last quarter. Redmile Group LLC boosted its position in shares of 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after purchasing an additional 188,655 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in 4D Molecular Therapeutics during the 3rd quarter worth approximately $166,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $6.36 on Wednesday. The stock has a market capitalization of $294.02 million, a price-to-earnings ratio of -2.23 and a beta of 2.74. The business has a 50-day moving average of $7.15 and a 200 day moving average of $12.34. 4D Molecular Therapeutics has a 12 month low of $5.22 and a 12 month high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.